SprinkleBit | Lexicon Pharmaceuticals, Inc. (LXRX)

Community actions

Lexicon Pharmaceuticals, Inc. news

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
A diabetes drug, twice rejected, stumbles again — but its developer persists
Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024
Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss
Sector Update: Health Care Stocks Rise Late Afternoon
Top Midday Decliners
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting
New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024
Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe

Recent Motivations

Lou Könik
Bought

35 shares of
- 💡 Litar på magkänslan
F1dd092
Sold

20 shares of
- 💵 Frigör lite SprinkleBucks
F1dd092
Sold

20 shares of
- 💵 Frigör lite SprinkleBucks
Thomas Lindow
Bought

49 shares of
- 📊 Jag tycker den är undervärderad just nu
F1dd092
Bought

40 shares of
- 💡 Litar på magkänslan

05 July, 3:59 PM EST/EDT	Open$1.66	Ask$1.67 x 0	P/E-2.42
LXRX	Day$1.62 - $1.67	Bid$1.66 x 0	Dividend (Yield %)$0.00 (0.00%)
Lonnel Coats	52 Week$0.00 - $3.78	Volume39,189	US stocks data provided for free by IEX.
http://www.lexpharma.com	Mkt. Cap.$409.02M	EPS-1.00

Lexicon Pharmaceuticals, Inc.